168.86
+2.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neurocrine Biosciences
From its filings with the US Securities and Exchange Commission
Neurocrine Biosciences is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NBIX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $2.86bn and net income of $478.6m. At that date it held total assets of $4.63bn and shareholders' equity of $3.25bn. By business, Net product sales brought in 99.1% of revenue, followed by Collaboration revenues at 0.9%.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. In addition, we have a diversified portfolio of multiple compounds in mid- to late-phase development across our core therapeutic areas and an expanding early-phase pipeline that includes a range of modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.
We launched INGREZZA® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of TD in May 2017 and for the treatment of chorea associated with Huntington's disease in August 2023 and launched CRENESSITY® (crinecerfont) in the U.S. as a first-in-class FDA-approved treatment of CAH in December 2024.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 May 1996
- Employees
- 2,000
- Website
- neurocrine.com ↗
- Head office
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. William RastetterNon-Executive Independent Chairman of the Board$501,275
- Dr. Kyle GanoPresident, Chief Executive Officer, Director, since 2011$8.5m
- Mr. Matthew AbernethyChief Financial Officer$6.6m
- Ms. Julie CookeChief Human Resources Officer
- Mr. Lewis ChoiChief Information Officer
- Dr. Jude OnyiaChief Scientific Officer$7.0m
- Mr. Eric BenevichChief Commercial Officer$6.3m
- Mr. David BoyerChief Corporate Affairs Officer
- Dr. Ingrid DelaetChief Regulatory Officer
- Mr. Sanjay KeswaniChief Medical Officer
- Mr. Darin LippoldtChief Legal Officer, Corporate Secretary$4.7m
- Dr. Kevin GormanDirector, since 2003$16.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 48
- Social
- 97
- Governance
- 62
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.